NEW YORK, March 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=136012&from=4 CLASS PERIOD: February 5, 2020 to August 14, 2022ALLEGATI ...

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=135482&from=4CLASS PERIOD: February 5, 2020 to August 14, 2022ALLEGATIO ...

Core Viewpoint - The article discusses the potential of bispecific antibodies to replace CAR-T therapies in the treatment of multiple myeloma, highlighting insights from Dr. Syed Abbas Ali of Johns Hopkins University [3][4][6]. Group 1: Bispecific Antibodies vs. CAR-T Therapies - Dr. Ali emphasizes that bispecific antibodies, particularly those targeting BCMA and CD3, may surpass CAR-T therapies in efficacy and safety, especially as physicians learn to manage toxicity better [6][7]. - The total response rate for Gilead-Arcellx's Anito-cel is reported at 100%, with lower toxicity compared to Johnson & Johnson's Carvykti, which is primarily used for high-risk patients [4][5]. - The safety profile of Anito-cel shows significant advantages, with a median onset of cytokine release syndrome (CRS) at 2 days and a duration of 3 days, compared to Carvykti's 7 days onset and 4 days duration [5]. Group 2: Market Dynamics and Competitive Landscape - The article notes that Blenrep from GlaxoSmithKline faces challenges in regaining market trust after its previous withdrawal, with analysts expressing concerns over its sales growth potential [8]. - Sanofi's Sarclisa is seen as a competitor to Johnson & Johnson's Darzalex, but the latter's ease of use as a monthly subcutaneous injection poses a significant challenge for Sarclisa [9]. - The article highlights the increasing accessibility of blood component apheresis for CAR-T therapy, which has improved patient treatment options [4].

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=134398&wire= ...

Core Insights - GSK's shares have increased by approximately 8% since the last earnings report, outperforming the S&P 500 [1] - The company reported core earnings of 59 cents per American depositary share (ADS), exceeding the Zacks Consensus Estimate of 53 cents, although core earnings declined by 20% year-over-year [2] - Quarterly revenues rose by 1% to $10.4 billion (£8.12 billion), surpassing the Zacks Consensus Estimate of $10.00 billion [2] Segment Performance - Specialty Medicines segment saw a 17% increase in sales, driven by strong growth in HIV, Immunology/Respiratory, and Oncology [5] - General Medicines sales increased by 6%, supported by strong demand for the asthma inhaler Trelegy Ellipta [14] - Vaccine sales declined by 12%, primarily due to lower sales of the RSV vaccine Arexvy and shingles vaccine Shingrix [16] Specialty Medicines Details - HIV sales rose by 14%, with significant contributions from the dolutegravir franchise, which saw an 8% increase in sales [5][6] - New long-acting medicines Cabenuva and Apretude experienced sales growth of 43% and 65%, respectively, contributing over 50% to total HIV growth [7] - Oncology sales surged by 72%, driven by strong demand for Jemperli and Ojjaara [8] General Medicines Insights - Trelegy Ellipta sales surged by 17%, while sales of established drugs like Advair/Seretide declined by 2% [14] - General Medicines sales are expected to remain stable in 2025, with volume growth offset by pricing pressures [15] Vaccine Performance - Arexvy sales fell by 69% year-over-year, while Shingrix sales decreased by 4% due to lower demand [16][17] - Meningitis vaccine Bexsero sales rose by 39%, while Menveo sales declined by 41% [19] Financial Outlook - GSK expects sales growth of 3-5% in 2025, with Specialty Medicines driving this growth [21] - The company plans to buy back up to £2 billion of shares over the next 18 months [22] - A dividend of 64p is planned for 2025, reflecting a 5% increase year-over-year [23] Long-Term Guidance - GSK raised its long-term sales outlook for 2031 to over £40 billion, up from a previous estimate of over £38 billion [24] - Specialty Medicines are expected to account for more than 50% of sales by 2031 [24] - The company maintained its guidance for 2021-2026, expecting sales growth of more than 7% and core operating profit growth of more than 11% on a CAGR basis [25]

Investment Rating - The investment rating for the pharmaceutical industry is "Outperform the Market" (maintained) [1] Core Insights - The main growth driver remains the launch of innovative products, particularly in the GLP-1 category, with significant revenue increases reported by companies like Eli Lilly and Novo Nordisk [3] - The report highlights the strong performance of key products across various therapeutic areas, including oncology, metabolism, and immunology, with notable sales growth percentages [3] Summary by Sections 01 Overview of Overseas Pharmaceutical Companies Q4 2024 and Annual Performance - Eli Lilly's revenue increased by 32% in 2024, driven by GLP-1 products [3] - Novo Nordisk's sales reached approximately $40.5 billion, a 25% increase, with significant contributions from GLP-1 products [29] - AstraZeneca and Merck also reported strong growth, with revenue increases of 21% and 10% respectively [3] 02 Performance Review of Overseas Pharmaceutical Companies - Eli Lilly's Q4 sales reached $13.5 billion, a 45% increase, with GLP-1 products contributing significantly [18] - Novo Nordisk's GLP-1 products achieved sales of approximately $22.5 billion, with a 20% increase in the diabetes segment [29] - JNJ's pharmaceutical segment reported $14.3 billion in Q4, with oncology products driving growth [40] R&D Investment - The top 15 pharmaceutical companies invested over $150 billion in R&D in 2024, a 7% increase year-on-year, with a research expense ratio of 21.8% [8] Sales Performance in China - Seven overseas pharmaceutical companies reported combined sales of approximately 515 billion RMB in Q4 2024, with a year-on-year growth of 10% [14]

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=134353&wire=4GSK in ...

Core Viewpoint - GSK plc is facing allegations related to misleading statements regarding the withdrawal of Zantac from the market, with claims that the company was aware of the source of NDMA for nearly 40 years before the product's removal [1]. Group 1: Allegations and Legal Context - The class period for the allegations against GSK spans from February 5, 2020, to August 14, 2022 [1]. - Defendants allegedly misrepresented to investors that GSK removed Zantac based on available information and correspondence with regulators, while also claiming that there was no evidence linking ranitidine therapy to cancer [1]. - The complaint asserts that GSK's representations were materially false or misleading, as the company had prior knowledge of the NDMA source [1]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased GSK shares during the specified class period are encouraged to register for the class action, with a deadline set for April 7, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm aims to protect the rights of investors affected by deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock value [3].

Core Viewpoint - A class action securities lawsuit has been filed against GSK plc, alleging securities fraud that affected investors between February 5, 2020, and August 14, 2022 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that GSK misled investors regarding the removal of Zantac from the market, stating it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years prior to the withdrawal [2]. - GSK assured investors that there was no evidence linking ranitidine therapy to cancer, which the lawsuit argues was materially false or misleading [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until April 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of GSK plc American Depositary Receipts (ADRs) about a class action lawsuit related to misleading statements made by GSK regarding the withdrawal of Zantac from the market and its implications for investors [1][4][5]. Group 1: Class Action Details - The class action pertains to GSK ADRs purchased between February 5, 2020, and August 14, 2022, with a lead plaintiff deadline of April 7, 2025 [1][2]. - Investors who purchased GSK ADRs during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. Group 2: Allegations Against GSK - The complaint alleges that GSK misrepresented the reasons for withdrawing Zantac, claiming it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years [4][5]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which was later revealed to be misleading as they had concealed an internal study implicating their liability [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel, highlighting its track record in securities class actions and significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].